Ascendis Pharma A/S (NASDAQ:ASND) vs. Sangamo Therapeutics (NASDAQ:SGMO) Head-To-Head Contrast

Ascendis Pharma A/S (NASDAQ:ASND) and Sangamo Therapeutics (NASDAQ:SGMO) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

Profitability

This table compares Ascendis Pharma A/S and Sangamo Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	-54.94%	N/A	-24.31%
Sangamo Therapeutics	-77.48%	-293.05%	-63.85%

Earnings and Valuation

This table compares Ascendis Pharma A/S and Sangamo Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$393.54 million	33.05	-$409.12 million	($5.16)	-40.86
Sangamo Therapeutics	$57.80 million	3.65	-$97.94 million	($0.29)	-2.41

Sangamo Therapeutics has lower revenue, but higher earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Ascendis Pharma A/S and Sangamo Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	1	0	15	0	2.88
Sangamo Therapeutics	1	2	4	0	2.43

Ascendis Pharma A/S presently has a consensus target price of $244.36, indicating a potential upside of 15.90%. Sangamo Therapeutics has a consensus target price of $4.50, indicating a potential upside of 543.78%. Given Sangamo Therapeutics’ higher possible upside, analysts clearly believe Sangamo Therapeutics is more favorable than Ascendis Pharma A/S.

Volatility and Risk

Ascendis Pharma A/S has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Comparatively, Sangamo Therapeutics has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500.

Institutional and Insider Ownership

56.9% of Sangamo Therapeutics shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Comparatively, 4.1% of Sangamo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Ascendis Pharma A/S beats Sangamo Therapeutics on 8 of the 14 factors compared between the two stocks.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.